These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37531029)

  • 41. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration.
    ElSheikh RH; Chauhan MZ; Sallam AB
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration.
    Cohen SY; Dominguez M; Coscas F; Faure C; Baillif S; Oubraham H; Kodjikian L; Weber M;
    Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):959-969. PubMed ID: 36399178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina.
    Demir N; Sevincli S; Kayhan B; Sonmez M
    Cutan Ocul Toxicol; 2021 Jun; 40(2):135-139. PubMed ID: 33944638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.
    Ferreira A; Sagkriotis A; Olson M; Lu J; Makin C; Milnes F
    PLoS One; 2015; 10(7):e0133968. PubMed ID: 26208030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration.
    Berkowitz ST; Patel S
    Ophthalmol Retina; 2021 Apr; 5(4):357-364. PubMed ID: 32818623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen.
    Aslanis S; Amrén U; Lindberg C; Epstein D
    Ophthalmol Retina; 2022 Jan; 6(1):15-20. PubMed ID: 33775926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients.
    Rahman W; Chen FK; Yeoh J; da Cruz L
    Graefes Arch Clin Exp Ophthalmol; 2013 Jun; 251(6):1483-8. PubMed ID: 23160538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insights From Survival Analyses During 12 Years of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
    Fu DJ; Keenan TD; Faes L; Lim E; Wagner SK; Moraes G; Huemer J; Kern C; Patel PJ; Balaskas K; Sim DA; Bunce C; Stratton I; Keane PA
    JAMA Ophthalmol; 2021 Jan; 139(1):57-67. PubMed ID: 33211064
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.
    Gallardo M; Munk MR; Kurmann T; De Zanet S; Mosinska A; Karagoz IK; Zinkernagel MS; Wolf S; Sznitman R
    Ophthalmol Retina; 2021 Jul; 5(7):604-624. PubMed ID: 33971352
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab.
    Parikh R; Avery RL; Saroj N; Thompson D; Freund KB
    JAMA Ophthalmol; 2019 Aug; 137(8):914-920. PubMed ID: 31294771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
    Chan CK; Lalezary M; Abraham P; Elman M; Beaulieu WT; Lin SG; Khurana RN; Bansal AS; Wieland MR; Palmer JD; Chang LK; Lujan BJ; Yiu G;
    Ophthalmol Retina; 2022 Jun; 6(6):484-494. PubMed ID: 35121216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8).
    Horner F; Lip PL; Clark H; Chavan R; Sarmad A; Mushtaq B
    Clin Ophthalmol; 2019; 13():2461-2467. PubMed ID: 31849444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
    Evans RN; Reeves BC; Maguire MG; Martin DF; Muldrew A; Peto T; Rogers C; Chakravarthy U
    JAMA Ophthalmol; 2020 Oct; 138(10):1043-1051. PubMed ID: 32816002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aflibercept in real-life for the treatment of age-related macular degeneration using a treat and extend protocol: The Armada study.
    Gascon P; Ramtohul P; Delaporte C; Kerever S; Denis D; Comet A
    Eur J Ophthalmol; 2022 Jan; 32(1):356-363. PubMed ID: 33779324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ten-year outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular disease: A single-centre French study.
    Wolff B; Macioce V; Vasseur V; Castelnovo L; Michel G; Nguyen V; Daien V; Mauget-Faÿsse M; Gillies M
    Clin Exp Ophthalmol; 2020 Jul; 48(5):636-643. PubMed ID: 32112667
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospective Cohort Study.
    Lee WA; Shao SC; Liao TC; Lin SJ; Lai CC; Lai EC
    BioDrugs; 2022 Mar; 36(2):205-216. PubMed ID: 35230656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glaucoma progression in patients receiving intravitreal anti-VEGF treatment for neovascular age-related macular degeneration.
    Pirinen I; Leinonen S; Helminen M; Hujanen P; Vaajanen A; Tuulonen A; Uusitalo-Järvinen H
    Acta Ophthalmol; 2023 May; 101(3):261-265. PubMed ID: 36398433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration.
    Talks JS; Lotery AJ; Ghanchi F; Sivaprasad S; Johnston RL; Patel N; McKibbin M; Bailey C; Mahmood S;
    Ophthalmology; 2016 Feb; 123(2):337-343. PubMed ID: 26578446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.
    Ciulla TA; Hussain RM; Taraborelli D; Pollack JS; Williams DF
    Ophthalmol Retina; 2022 Sep; 6(9):796-806. PubMed ID: 35381391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.